Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Bio-Rad (BIO) Q4 Earnings Miss Estimates, Operating Margin Up
12:02pm, Friday, 17'th Feb 2023
Excluding COVID-related sales, Life Science revenues at Bio-Rad (BIO) increase 28.1%, primarily driven by Droplet Digital PCR, process chromatography, Western blotting and qPCR products.
Bio-Rad Laboratories, Inc. (BIO) Q4 2022 Earnings Call Transcript
11:13pm, Thursday, 16'th Feb 2023
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q4 2022 Earnings Conference Call February 16, 2023 5:00 PM ET Company Participants Edward Chung - Vice President, Investor Relations Ilan Daskal - Chief Financia
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates
06:49pm, Thursday, 16'th Feb 2023
Bio-Rad (BIO) delivered earnings and revenue surprises of -4.06% and 2.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
09:00am, Friday, 06'th Jan 2023
HERCULES, Calif.--( BUSINESS WIRE )--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for t
Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
02:11pm, Thursday, 05'th Jan 2023 Zacks Investment Research
Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.
Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
03:42pm, Wednesday, 04'th Jan 2023
Punishment of both Bio-Rad Laboratories, Inc. and Sartorius AG continued throughout the final stages of 2022. Bio-Rad Laboratories had an equally challenging Q3, setting up Q4 and FY22 numbers as key
Bio-Rad (BIO) Core Diagnostic Sales Grow Amid Supply Challenges
02:44pm, Friday, 23'rd Dec 2022 Zacks Investment Research
Bio-Rad's (BIO) underlying Life Science currency-neutral core revenue growth is primarily driven by Western loading, qPCR, process media and antibody products sales.
Bio-Rad (BIO) Core Diagnostic Sales Grow Amid Supply Challenges
11:17am, Friday, 23'rd Dec 2022
Bio-Rad's (BIO) underlying Life Science currency-neutral core revenue growth is primarily driven by Western loading, qPCR, process media and antibody products sales.
The Bunny Portfolio Has Averaged 13.6% Per Year
10:56am, Monday, 12'th Dec 2022
What do you call a stock that has a great earnings growth history, yet sells for modest price?
Bio Rad Has Almost 40% Upside On Revenue Acceleration And Margin Improvement, Analyst Says
07:30pm, Wednesday, 07'th Dec 2022 Benzinga
RBC Capital Markets initiated coverage on Bio-Rad Laboratories Inc (NYSE: BIO) with an Outperform rating and a $565 price target.
The analyst writes that Bio-Rad has evolved as a public company ov
These Are the Five Best and Worst Performing Healthcare Stocks in October 2022
08:02pm, Monday, 28'th Nov 2022
The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.
Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Down
05:01pm, Friday, 28'th Oct 2022 Zacks Investment Research
Bio-Rad's (BIO) third-quarter revenues decline mainly as a result of lower COVID-related sales compared with the year-ago period.
Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Down
02:18pm, Friday, 28'th Oct 2022
Bio-Rad's (BIO) third-quarter revenues decline mainly as a result of lower COVID-related sales compared with the year-ago period.
Bio-Rad Laboratories, Inc. (BIO) Q3 2022 Earnings Call Transcript
10:23pm, Thursday, 27'th Oct 2022
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q3 2022 Earnings Conference Call October 27, 2022 5:00 PM ET Company Participants Edward Chung - VP, IR Ilan Daskal - EVP & CFO Andrew Last - EVP & COO Norman Sc
Bio-Rad Laboratories (BIO) Surpasses Q3 Earnings Estimates
09:45pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 0.39% and 1.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
